PDCD1 and non-small cell lung carcinoma: Similarly, the multivariate analysis of data from patients with NSCLC before and after second-line therapy with anti-PD-1/PD-L1 antibodies found that NK cells were the only lymphocyte type the number of which was a positive predictor of progression-free survival and overall survival [178].